Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer specializing in the research, development, manufacture, and distribution of orphan drugs, including anti-cancer drugs and medications for leukemia, as well as high-quality generic medicines. Based in Japan, the company focuses on addressing unmet medical needs in areas such as childhood cancers, central nervous system diseases, and hepatic diseases. It operates with a commitment to providing reliable treatment alternatives from the patient's perspective. Ohara Pharmaceutical has actively invested $39.6 million across three funding rounds from June 2023 to April 2025, targeting health tech companies in Africa. Investments include a $30 million Series B round in Helium Health in Nigeria, which provides digital health records, telemedicine, and clinic financing, and two rounds totaling $9.6 million in MYDAWA in Kenya, a platform for ordering medicines and healthcare essentials with fast delivery. The firm has participated in stages such as Series B, venture (round not specified), and other, with a clear geographic focus on Kenya and Nigeria. The company has co-invested alongside partners including AAIC Investment, Creadev, IFU, and Alta Semper in these African health tech deals.
Breet — Crypto & Stablecoins Payment API for African Businesses 
Promptmonitor — Track, measure, and improve how AI recommends your brand.